Get started
Work

Phase 3, multicenter, randomized, controlled open-label study: Efficacy and safety of M701 (EpCAM×CD3 bispecific antibody) intraperitoneal infusion in advanced epithelial solid tumor with malignant ascites vs paracentesis.

Year: 2026
Type: conference-abstract
DOI: 10.1200/jco.2026.44.16_suppl.104
Authors: Jianming Xu, Yanqiao Zhang, Rong-Bo Lin, Xinyu Qian, Weijie Zhang, Caigang Liu, Xizhi Zhang, Jun Zhang, Huiqing Zhang, Bihui Li, Shengmian Li, Haiyan Liu, Jun Zhao, Jiayi Li, Linzhi Lu, Meili Sun, Jun Cai, Hanxiang An, Pengfei Zhou, Shaoyi Huang
Institutions: Chinese PLA General Hospital, Third Affiliated Hospital of Harbin Medical University, Fujian Provincial Cancer Hospital, Hangzhou Cancer Hospital, First Affiliated Hospital of Zhengzhou University, Sheng Jing Hospital, China Medical University, Northern Jiangsu People's Hospital, Third People's Hospital of Chengdu, Jiangxi Provincial Cancer Hospital, Guilin Medical University, Hebei Medical University, Fourth Hospital of Hebei Medical University, Shandong First Medical University, Changzhi Medical College, First Affiliated Hospital of Xiamen University, Jinan Central Hospital, Yangtze University, Wuhan YZY Biopharma (China)
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: closed
OpenAlex ID: W7162521315
Cites:
Cited by:
Related to: